IGHG3 and Parkinson disease: The peptoid PD2 (Table 2) from library 2 was identified as an encouraging candidate which is able to bind significantly higher levels of IgG3 antibodies in PD versus healthy subjects with a 68% accuracy; this is improved up to 84% in the identification of de novo PD.